Literature DB >> 8702379

Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study.

J W Middleton1, P J Siddall, S Walker, A R Molloy, S B Rutkowski.   

Abstract

Spasticity and pain are common disabling sequelae following spinal cord injury (SCI) and are often difficult to manage. The two problems are also not infrequently related. A variety of pharmacological and other approaches have been described for management of these problems in SCI. This case study reports a 32-year-old woman with an established incomplete C5 tetraplegia (anterior cord syndrome) who developed severe, intractable anal spasm following a hemorrhoidectomy, which persisted despite very good healing. This prevented evacuation of her bowels and resulted in severe rectal pain and episodes of autonomic dysreflexia. Attempts to modify the rate and mode of delivery of intrathecal baclofen through an existing programmable infusion pump failed to reduce anal sphincter spasm or improve symptoms. A right-sided pudendal block with lignocaine provided some relief. Clonidine was added to baclofen in the pump reservoir and both drugs were administered intrathecally in combination. This resulted in an immediate improvement in anal sphincter spasm and pain relief, allowing rapid reestablishment of her normal bowel pattern without need for any supplemental analgesia. It appears that intrathecal clonidine may have an important role in the treatment of spasticity, either as a single or an adjuvant agent, when intrathecal baclofen alone is ineffective or there is increasing tolerance to baclofen. Intrathecal clonidine may also prove useful in the management of intractable neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702379     DOI: 10.1016/s0003-9993(96)90264-6

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  10 in total

1.  Use of intrathecal clonidine in patients with multiple sclerosis or spastic paraparesis.

Authors:  Joseph K Ho; Saud A Sadiq
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

Review 2.  Evaluation and Management of SCI-Associated Pain.

Authors:  Michael Saulino; Justin F Averna
Journal:  Curr Pain Headache Rep       Date:  2016-09

Review 3.  Pharmacologic treatment of neuropathic pain.

Authors:  M S Wallace
Journal:  Curr Pain Headache Rep       Date:  2001-04

4.  Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia.

Authors:  T Fuchigami; O Kakinohana; M P Hefferan; N Lukacova; S Marsala; O Platoshyn; K Sugahara; T L Yaksh; M Marsala
Journal:  Neuroscience       Date:  2011-08-16       Impact factor: 3.590

5.  Neutralizing intraspinal nerve growth factor blocks autonomic dysreflexia caused by spinal cord injury.

Authors:  N R Krenz; S O Meakin; A V Krassioukov; L C Weaver
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

6.  Spinal Cord Injury Provoked Neuropathic Pain and Spasticity, and Their GABAergic Connection.

Authors:  Ankita Bhagwani; Manjeet Chopra; Hemant Kumar
Journal:  Neurospine       Date:  2022-09-30

7.  Combination Drug Therapy for Pain following Chronic Spinal Cord Injury.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Pain Res Treat       Date:  2012-03-18

Review 8.  Intrathecal analgesic drug therapy.

Authors:  Alan Farrow-Gillespie; Kimberly M Kaplan
Journal:  Curr Pain Headache Rep       Date:  2006-02

Review 9.  Spinal drug delivery.

Authors:  T S Grabow; D Derdzinski; P S Staats
Journal:  Curr Pain Headache Rep       Date:  2001-12

Review 10.  Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient.

Authors:  Jose De Andres; Salim Hayek; Christophe Perruchoud; Melinda M Lawrence; Miguel Angel Reina; Carmen De Andres-Serrano; Ruben Rubio-Haro; Mathew Hunt; Tony L Yaksh
Journal:  Front Pain Res (Lausanne)       Date:  2022-06-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.